Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bismuth/Amoxicillin/PCAB Triple Therapy for H. pylori in Taiwan
NCT07142798Enrolling by invitation
- Sponsor
- Kaohsiung Medical University
- Start
- Sep 2024
- Primary completion
- Dec 2025
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Open-label trial of vonoprazan, amoxicillin and bismuth subcitrate in Helicobacter pylori infection, sponsored by Kaohsiung Medical University. Primary endpoint: Eradicaton rate of Helicobacter pylori. Started Sep 2024; status: enrolling by invitation.
02
Drugs
vonoprazanamoxicillinbismuth subcitrate
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT07142798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07142798.